CD80 as an Important Immune Mediator and Therapeutic Target in Atherosclerosis. (PubMed, Int J Mol Sci) - Sep 27, 2026 - "Molecular imaging agents targeting CD80/CD86, repurposed CTLA-4-Ig biologics such as abatacept, and antigen-specific tolerogenic dendritic cell strategies together constitute an emerging translational pipeline. To our knowledge, this is the first review to integrate CD80's structural and receptor pharmacology with its cellular sources in the plaque, preclinical genetic and pharmacological evidence, human plaque and biomarker data, molecular imaging approaches, and checkpoint inhibitor-associated cardiovascular toxicity within a single translational framework. This review synthesizes the structural biology, cellular sources, preclinical genetics, human plaque and biomarker data, and therapeutic and diagnostic implications of CD80 as an immune mediator and candidate therapeutic target in atherosclerosis."
IO biomarker • Journal • Review • Atherosclerosis • Cardiovascular • Dyslipidemia • Oncology • CD80 • CD86 • PD-L1
|
|
Aleksey Vatlin; Alexander Blagov; Anastasia Maksaeva; Daria Borodko
|